The invention discloses an in-vitro culture method for improving the activity of umbilical cord blood derived NK cells. The method adopts the following raw materials: a biosafety cabinet, a flow cytometer, a horizontal temperature control centrifuge, a sterilization pot, a CO2 incubator, an inverted microscope, a three-classification blood analyzer, a cell counter, a pipettor, refrigerators with the temperatures of -20 DEG C and 4 DEG C, a 75cm<2> culture bottle, a 225cm<2> culture bottle, a 2L culture bag, a 10ml transfer pipette, a 50ml efficient centrifuge tube, 15ml and 50ml centrifuge tubes, a 250ml centrifuge tube, medical sterile gloves, disposable sterile cap and sterile gloves, a serum-free culture medium LonzaX-VIVO15, recombinant interleukin 2, recombinant interleukin 15, a 0.4%trypan blue solution, physiological saline, human lymphocyte separation liquid, gamma interferon and recombinant interleukin 1[alpha]. According to the method, lentinan is added into related cytokines to culture the umbilical cord blood NK cells, so that the cost of culturing the NK cells by the method is not high, the proliferation speed is increased by 13-15 days, the proliferation multiple isincreased by about 270 times, the cell activity is high, and the cell phenotype is 91%.